NCT01221168 Epidemiologic and Genetic Study on Familial Prostate Cancer
| NCT ID | NCT01221168 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre de Recherche sur les Pathologies Prostatiques |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 1996-10 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 1996-10 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aims of the study are: * to identify genetic and molecular factors (rare mutations, polymorphisms) involved in the natural history of prostate cancers and their response to treatment, * to evaluate and deduce their medical applications for screening and therapeutic management of these tumors.
Eligibility Criteria
Inclusion Criteria: * patient with a histological confirmed prostate cancer * member of a hereditary prostate cancer family * healthy control men without prostate cancer Exclusion Criteria: * Absence of signed informed consent * refusal to participate in the study
Contact & Investigator
Olivier Cussenot, MD, Ph.D.
PRINCIPAL INVESTIGATOR
Centre de Recherche sur les Pathologies Prostatiques
Frequently Asked Questions
Who can join the NCT01221168 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01221168 currently recruiting?
Yes, NCT01221168 is actively recruiting participants. Contact the research team at olivier.cussenot@cerepp.org for enrollment information.
Where is the NCT01221168 trial being conducted?
This trial is being conducted at Angers, France, Brest, France, Dijon, France, Paris, France and 1 additional location.
Who is sponsoring the NCT01221168 clinical trial?
NCT01221168 is sponsored by Centre de Recherche sur les Pathologies Prostatiques. The principal investigator is Olivier Cussenot, MD, Ph.D. at Centre de Recherche sur les Pathologies Prostatiques. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.